FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921564147> ?p ?o ?g. }

• W2921564147 abstract "29 Background: Salvage external beam radiotherapy (RT) and hormonal therapy improves survival over RT alone in men with non-metastatic hormone naïve PC and PSA recurrence after radical prostatectomy (RP). We investigated the safety/efficacy of enzalutamide with salvage RT and ADT in this setting. Methods: This was a 3 center prospective phase 2 single arm clinical trial in the Dept of Defense Prostate Cancer Clinical Trials Consortium. Eligibility: Gleason 7-10 PC and PSA recurrence within 4 years (yrs) of RP, PSA 0.2-4.0, no prior hormonal therapy, and no metastases on CT/Bone Scan imaging. Men received 6 months (mos) of ADT with 160 mg/d enzalutamide and 66 Gy RT to the prostate bed. Primary endpoint was 2 yr PFS with testosterone (T) recovery to >100 ng/dl. Secondary objectives included PSA nadir, 3 yr PFS, safety and patient reported quality-of-life over time. This trial was designed with 84% power to detect a 20% improvement in 2 yr PFS vs historic data and a 1-sided alpha of 0.05. Results: We enrolled 38 men (90% white, 8% black, 2% Asian); 37 (97%) completed therapy and were evaluable with T recovery at 2 yrs. Median age was 64 yrs; 47% Gleason 8-10, 79% T3/T4 disease, 21% had resected N+ PC; median PSA was 0.4 (0.19-4.19). Median follow-up is 29.5 mo. Treatment was well tolerated with 11 patients (29%) experiencing G3 toxicities (including 4 HTN, 2 urinary retention, 2 CV events); no G4-5 or unexpected toxicities were observed. T recovery occurred in 35 (95%) at 12 mos. The primary endpoint of 2 yr PFS was 65% (95% CI: 47%-78% vs. historic controls with 51% 2 yr PFS rate) among the 37 patients with T recovery. PSA remained at undetectable levels in 69% at 2 yrs. The 3 yr PFS was 53% (95% CI: 36%, 68%). QOL data over time suggest short term reductions in urinary and sexual function with recovery by 12-24 mo in most men. Conclusions: Salvage enzalutamide and ADT for 6 months with RT following RP for men with PSA recurrent high risk PC is safe, and demonstrates encouraging efficacy at 2 and 3 years. Most men have testosterone recovery at 1 year. These data warrant prospective controlled phase 3 trials to assess the impact of potent AR inhibition in this curative intent setting. Clinical trial information: NCT02057939." @default.
• W2921564147 created "2019-03-22" @default.
• W2921564147 creator A5000997350 @default.
• W2921564147 creator A5003209805 @default.
• W2921564147 creator A5003532001 @default.
• W2921564147 creator A5006619073 @default.
• W2921564147 creator A5013457105 @default.
• W2921564147 creator A5023914087 @default.
• W2921564147 creator A5033510051 @default.
• W2921564147 creator A5033835226 @default.
• W2921564147 creator A5038489185 @default.
• W2921564147 creator A5047408345 @default.
• W2921564147 creator A5058429903 @default.
• W2921564147 creator A5061888417 @default.
• W2921564147 creator A5069167592 @default.
• W2921564147 creator A5071072809 @default.
• W2921564147 creator A5071773606 @default.
• W2921564147 creator A5074542465 @default.
• W2921564147 creator A5078940541 @default.
• W2921564147 creator A5080856747 @default.
• W2921564147 date "2019-03-01" @default.
• W2921564147 modified "2023-10-03" @default.
• W2921564147 title "Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial." @default.
• W2921564147 doi "https://doi.org/10.1200/jco.2019.37.7_suppl.29" @default.
• W2921564147 hasPublicationYear "2019" @default.
• W2921564147 type Work @default.
• W2921564147 sameAs 2921564147 @default.
• W2921564147 citedByCount "2" @default.
• W2921564147 countsByYear W29215641472020 @default.
• W2921564147 countsByYear W29215641472021 @default.
• W2921564147 crossrefType "journal-article" @default.
• W2921564147 hasAuthorship W2921564147A5000997350 @default.
• W2921564147 hasAuthorship W2921564147A5003209805 @default.
• W2921564147 hasAuthorship W2921564147A5003532001 @default.
• W2921564147 hasAuthorship W2921564147A5006619073 @default.
• W2921564147 hasAuthorship W2921564147A5013457105 @default.
• W2921564147 hasAuthorship W2921564147A5023914087 @default.
• W2921564147 hasAuthorship W2921564147A5033510051 @default.
• W2921564147 hasAuthorship W2921564147A5033835226 @default.
• W2921564147 hasAuthorship W2921564147A5038489185 @default.
• W2921564147 hasAuthorship W2921564147A5047408345 @default.
• W2921564147 hasAuthorship W2921564147A5058429903 @default.
• W2921564147 hasAuthorship W2921564147A5061888417 @default.
• W2921564147 hasAuthorship W2921564147A5069167592 @default.
• W2921564147 hasAuthorship W2921564147A5071072809 @default.
• W2921564147 hasAuthorship W2921564147A5071773606 @default.
• W2921564147 hasAuthorship W2921564147A5074542465 @default.
• W2921564147 hasAuthorship W2921564147A5078940541 @default.
• W2921564147 hasAuthorship W2921564147A5080856747 @default.
• W2921564147 hasConcept C121608353 @default.
• W2921564147 hasConcept C126322002 @default.
• W2921564147 hasConcept C126894567 @default.
• W2921564147 hasConcept C143998085 @default.
• W2921564147 hasConcept C2776235491 @default.
• W2921564147 hasConcept C2776551883 @default.
• W2921564147 hasConcept C2776694085 @default.
• W2921564147 hasConcept C2777899217 @default.
• W2921564147 hasConcept C2777911890 @default.
• W2921564147 hasConcept C2779466945 @default.
• W2921564147 hasConcept C2780192828 @default.
• W2921564147 hasConcept C2780775027 @default.
• W2921564147 hasConcept C2909113890 @default.
• W2921564147 hasConcept C509974204 @default.
• W2921564147 hasConcept C61367390 @default.
• W2921564147 hasConcept C71315377 @default.
• W2921564147 hasConcept C71924100 @default.
• W2921564147 hasConceptScore W2921564147C121608353 @default.
• W2921564147 hasConceptScore W2921564147C126322002 @default.
• W2921564147 hasConceptScore W2921564147C126894567 @default.
• W2921564147 hasConceptScore W2921564147C143998085 @default.
• W2921564147 hasConceptScore W2921564147C2776235491 @default.
• W2921564147 hasConceptScore W2921564147C2776551883 @default.
• W2921564147 hasConceptScore W2921564147C2776694085 @default.
• W2921564147 hasConceptScore W2921564147C2777899217 @default.
• W2921564147 hasConceptScore W2921564147C2777911890 @default.
• W2921564147 hasConceptScore W2921564147C2779466945 @default.
• W2921564147 hasConceptScore W2921564147C2780192828 @default.
• W2921564147 hasConceptScore W2921564147C2780775027 @default.
• W2921564147 hasConceptScore W2921564147C2909113890 @default.
• W2921564147 hasConceptScore W2921564147C509974204 @default.
• W2921564147 hasConceptScore W2921564147C61367390 @default.
• W2921564147 hasConceptScore W2921564147C71315377 @default.
• W2921564147 hasConceptScore W2921564147C71924100 @default.
• W2921564147 hasLocation W29215641471 @default.
• W2921564147 hasOpenAccess W2921564147 @default.
• W2921564147 hasPrimaryLocation W29215641471 @default.
• W2921564147 hasRelatedWork W1988315641 @default.
• W2921564147 hasRelatedWork W1989760222 @default.
• W2921564147 hasRelatedWork W2004176777 @default.
• W2921564147 hasRelatedWork W2024422893 @default.
• W2921564147 hasRelatedWork W2050195389 @default.
• W2921564147 hasRelatedWork W2058476300 @default.
• W2921564147 hasRelatedWork W2078781531 @default.
• W2921564147 hasRelatedWork W2155715335 @default.
• W2921564147 hasRelatedWork W2277659777 @default.
• W2921564147 hasRelatedWork W2561688274 @default.
• W2921564147 hasRelatedWork W2626118799 @default.
• W2921564147 hasRelatedWork W2756688586 @default.
• W2921564147 hasRelatedWork W2763760325 @default.
• W2921564147 hasRelatedWork W2764185003 @default.

• next